Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated

Kevin Camphausen, Cynthia Ménard, Mary Sproull, Elizabeth Goley, Samar Basu, C. Norman Coleman

Research output: Contribution to journalArticle

Abstract

Purpose Previous studies have demonstrated that urinary 8-iso-prostaglandin F (PGF) serves as a powerful biomarker of lipid peroxidation in diseases in which oxidative stress plays an important role in its pathophysiology. The goal of this study was to measure the urinary isoprostane levels in patients with prostate cancer treated with radiotherapy (RT) in an effort to determine whether isoprostane levels are elevated compared with in historical controls, whether the levels increase after RT, and whether such an increase would correlate positively with the degree of GU symptoms during treatment. Methods and materials Urine samples were obtained before and during RT from patients enrolled on a recently reported Phase III trial examining the therapeutic efficacy of ibuprofen in decreasing the acute urinary symptoms of RT. Radioimmunoassays were performed on urine samples for 8-iso-PGF or 15-keto-dihydro-PGF. Results Fifteen patients provided samples both before and during RT. The levels of 8-iso-PGF and 15-keto-dihydro-PGF in the urine samples obtained before prostate RT (0.27 and 0.41 nmol/mmol creatinine) did not differ appreciably from the values observed in a normal cohort (0.27 and 0.46 nmol/mmol creatinine) and did not change after RT (0.23 and 0.37 nmol/mmol creatinine). Conclusion We were unable to detect an increase in either 8-iso-PGF or 15-keto-dihydro-PGF in the urine of patients with prostate cancer compared with in historical normal controls. We were also unable to measure an increase in either of the eicosanoids during RT to the prostate gland.

Original languageEnglish (US)
Pages (from-to)1536-1539
Number of pages4
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume58
Issue number5
DOIs
StatePublished - Apr 1 2004
Externally publishedYes

Fingerprint

Isoprostanes
urine
Dinoprost
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Urine
creatinine
Creatinine
Prostate
prostate gland
radioimmunoassay
prostaglandins
Eicosanoids
biomarkers
Ibuprofen
Prostaglandins F
Lipid Peroxidation
Radioimmunoassay

Keywords

  • Free radicals
  • Prostaglandin isoprostanes
  • Prostate cancer
  • Radiotherapy
  • Urine

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated. / Camphausen, Kevin; Ménard, Cynthia; Sproull, Mary; Goley, Elizabeth; Basu, Samar; Coleman, C. Norman.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 58, No. 5, 01.04.2004, p. 1536-1539.

Research output: Contribution to journalArticle

Camphausen, Kevin ; Ménard, Cynthia ; Sproull, Mary ; Goley, Elizabeth ; Basu, Samar ; Coleman, C. Norman. / Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated. In: International Journal of Radiation Oncology, Biology, Physics. 2004 ; Vol. 58, No. 5. pp. 1536-1539.
@article{20758e9548534dbb8f8e4fb2b43e0a4b,
title = "Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated",
abstract = "Purpose Previous studies have demonstrated that urinary 8-iso-prostaglandin F (PGF)2α serves as a powerful biomarker of lipid peroxidation in diseases in which oxidative stress plays an important role in its pathophysiology. The goal of this study was to measure the urinary isoprostane levels in patients with prostate cancer treated with radiotherapy (RT) in an effort to determine whether isoprostane levels are elevated compared with in historical controls, whether the levels increase after RT, and whether such an increase would correlate positively with the degree of GU symptoms during treatment. Methods and materials Urine samples were obtained before and during RT from patients enrolled on a recently reported Phase III trial examining the therapeutic efficacy of ibuprofen in decreasing the acute urinary symptoms of RT. Radioimmunoassays were performed on urine samples for 8-iso-PGF2α or 15-keto-dihydro-PGF2α. Results Fifteen patients provided samples both before and during RT. The levels of 8-iso-PGF2α and 15-keto-dihydro-PGF2α in the urine samples obtained before prostate RT (0.27 and 0.41 nmol/mmol creatinine) did not differ appreciably from the values observed in a normal cohort (0.27 and 0.46 nmol/mmol creatinine) and did not change after RT (0.23 and 0.37 nmol/mmol creatinine). Conclusion We were unable to detect an increase in either 8-iso-PGF2α or 15-keto-dihydro-PGF2α in the urine of patients with prostate cancer compared with in historical normal controls. We were also unable to measure an increase in either of the eicosanoids during RT to the prostate gland.",
keywords = "Free radicals, Prostaglandin isoprostanes, Prostate cancer, Radiotherapy, Urine",
author = "Kevin Camphausen and Cynthia M{\'e}nard and Mary Sproull and Elizabeth Goley and Samar Basu and Coleman, {C. Norman}",
year = "2004",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2003.09.011",
language = "English (US)",
volume = "58",
pages = "1536--1539",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated

AU - Camphausen, Kevin

AU - Ménard, Cynthia

AU - Sproull, Mary

AU - Goley, Elizabeth

AU - Basu, Samar

AU - Coleman, C. Norman

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Purpose Previous studies have demonstrated that urinary 8-iso-prostaglandin F (PGF)2α serves as a powerful biomarker of lipid peroxidation in diseases in which oxidative stress plays an important role in its pathophysiology. The goal of this study was to measure the urinary isoprostane levels in patients with prostate cancer treated with radiotherapy (RT) in an effort to determine whether isoprostane levels are elevated compared with in historical controls, whether the levels increase after RT, and whether such an increase would correlate positively with the degree of GU symptoms during treatment. Methods and materials Urine samples were obtained before and during RT from patients enrolled on a recently reported Phase III trial examining the therapeutic efficacy of ibuprofen in decreasing the acute urinary symptoms of RT. Radioimmunoassays were performed on urine samples for 8-iso-PGF2α or 15-keto-dihydro-PGF2α. Results Fifteen patients provided samples both before and during RT. The levels of 8-iso-PGF2α and 15-keto-dihydro-PGF2α in the urine samples obtained before prostate RT (0.27 and 0.41 nmol/mmol creatinine) did not differ appreciably from the values observed in a normal cohort (0.27 and 0.46 nmol/mmol creatinine) and did not change after RT (0.23 and 0.37 nmol/mmol creatinine). Conclusion We were unable to detect an increase in either 8-iso-PGF2α or 15-keto-dihydro-PGF2α in the urine of patients with prostate cancer compared with in historical normal controls. We were also unable to measure an increase in either of the eicosanoids during RT to the prostate gland.

AB - Purpose Previous studies have demonstrated that urinary 8-iso-prostaglandin F (PGF)2α serves as a powerful biomarker of lipid peroxidation in diseases in which oxidative stress plays an important role in its pathophysiology. The goal of this study was to measure the urinary isoprostane levels in patients with prostate cancer treated with radiotherapy (RT) in an effort to determine whether isoprostane levels are elevated compared with in historical controls, whether the levels increase after RT, and whether such an increase would correlate positively with the degree of GU symptoms during treatment. Methods and materials Urine samples were obtained before and during RT from patients enrolled on a recently reported Phase III trial examining the therapeutic efficacy of ibuprofen in decreasing the acute urinary symptoms of RT. Radioimmunoassays were performed on urine samples for 8-iso-PGF2α or 15-keto-dihydro-PGF2α. Results Fifteen patients provided samples both before and during RT. The levels of 8-iso-PGF2α and 15-keto-dihydro-PGF2α in the urine samples obtained before prostate RT (0.27 and 0.41 nmol/mmol creatinine) did not differ appreciably from the values observed in a normal cohort (0.27 and 0.46 nmol/mmol creatinine) and did not change after RT (0.23 and 0.37 nmol/mmol creatinine). Conclusion We were unable to detect an increase in either 8-iso-PGF2α or 15-keto-dihydro-PGF2α in the urine of patients with prostate cancer compared with in historical normal controls. We were also unable to measure an increase in either of the eicosanoids during RT to the prostate gland.

KW - Free radicals

KW - Prostaglandin isoprostanes

KW - Prostate cancer

KW - Radiotherapy

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=1842424311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842424311&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2003.09.011

DO - 10.1016/j.ijrobp.2003.09.011

M3 - Article

C2 - 15050334

AN - SCOPUS:1842424311

VL - 58

SP - 1536

EP - 1539

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -